XVARY Composite Score
39
/ 100
Weak
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Atea is a clinical-stage drug developer trying to turn antiviral lab work into approved pills for viral infections.
How it gets paid
Last year Atea Pharma made n/a in revenue.
What just happened
The cleanest takeaway is still the ugly one: Atea has $0M in TTM revenue and quarterly losses continue.
At a Glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
17.1% return on capital — nothing to write home about
-$2.00 fy2024 eps est
$351M fy2021 rev est
XVARY composite: 39/100 — weak
What They Do
Atea is a clinical-stage drug developer trying to turn antiviral lab work into approved pills for viral infections.
This is not a scale story. It is a chemistry-and-cash story. Atea has 56 employees, $0 million in long-term debt, and a proprietary nucleos(t)ide platform (drug design system → a repeatable way to build antivirals → your bet is on the platform, not current sales).
How They Make Money
n/a
annual revenue
The Products That Matter
First pivotal readout
c-beyond
mid-2026 data
This is one of the two major Phase 3 checkpoints tied to the lead hepatitis C program. If you own the stock, this is one of the dates you are really owning.
mid-2026 catalyst
Second pivotal readout
c-forward
by year-end 2026
Second dataset, same broad thesis. One readout can move the stock. Two readouts shape whether the program starts to look durable or just hopeful.
year-end 2026 catalyst
Platform optionality
nucleos(t)ide platform
pre-revenue pipeline
This is the longer-dated part of the story. It matters, but right now the market is not paying up for broad platform dreams when the near-term proof point is still one lead program.
back-half upside
Key Numbers
$0M
ttm revenue
Deadpan fact bomb: the business the market values at roughly $486 million currently produces no trailing twelve-month revenue, per Yahoo Finance consensus.
-$2.00
2024 eps
's FY2024 EPS estimate shows losses getting worse, not better. Plain English: cash is still going out faster than progress is coming in.
39.4%
operating margin
Operating margin → profit after running the business → so what: for a pre-revenue biotech, this number is distorted by non-operating items and tells you less than the loss trend.
$0M
long-term debt
Zero long-term debt means the balance sheet is cleaner than most biotechs. That matters because dilution is bad, but debt plus dilution is worse.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
The cleanest takeaway is still the ugly one: Atea has $0M in TTM revenue and quarterly losses continue.
institutional data shows quarterly EPS of -$0.40 for 12/31/24 and FY2024 EPS of -$2.00. Yahoo Finance consensus lists last earnings at -$0.53 and trailing revenue at $0M, which is the quiet part said out loud.
$0M
revenue
-$0.40
q4 eps
39.4%
operating margin
the number that mattered
The number that matters is $0M in TTM revenue, because every other metric is really just a countdown to whether the pipeline becomes a business.
source: quarterly history and Yahoo Finance consensus, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
With AVIR, the risk is not abstract. You are not stress-testing a mature profit machine. You are asking whether a pre-revenue company with $351M in cash can turn two 2026 Phase 3 checkpoints into something durable.
Med
The lead readout fails
If the mid-2026 data disappoints, there is no product revenue to soften the blow and no broad operating story to fall back on.
Impact: the stock likely reprices around reduced program odds, not around minor estimate cuts.
Med
The timeline slips
A delayed readout does not break the science by itself, but it extends the wait and raises the market's sensitivity to cash usage.
Impact: delay risk keeps valuation in limbo longer and can turn patience into discounting.
Med
Cash lasts less comfortably than it looks
$351M sounds like a lot because it is. Trials are expensive because they are. If burn runs hotter than investors expect, the funding conversation gets louder.
Impact: even without debt, dilution risk can become the next debate if the runway stops looking generous.
Med
Volatility is structural
A 5 / 100 price stability score tells you the market will not treat bad headlines gently. Small-cap biotech does not do gentle.
Impact: position sizing matters. The business model does not give you much day-to-day fundamental cushioning.
You are not underwriting steady sales. You are underwriting trial outcomes against a $486M market cap.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Calendar
Mid-2026 Phase 3 data is the first real verdict
Expected mid-2026. This is the highest-signal event on the page. If the data disappoints, the cash balance stops being comforting and starts looking temporary.
Calendar
The second readout by year-end 2026 matters almost as much
A single good result can lift sentiment. Two good results start to look like a thesis. That is the difference between a bounce and a reset in how investors frame the company.
Metric
Cash runway is the operating metric that actually counts
The company had $351M at the end of 2025. Watch every update for how fast that pile shrinks, because pre-revenue biotech math is mostly time divided by burn.
Risk
Price swings are not noise here
A 5 / 100 price stability score tells you the market already expects violent repricing. If you own it, size it like a binary event name, not like a sleepy healthcare compounder.
Analyst Rankings
earnings predictability
20 / 100
in human-speak, you should not expect clean, stable quarter-to-quarter operating patterns from a company with no product revenue
balance-sheet read
B
cash and no debt keep the balance sheet from being the problem. the pipeline still is the story
price behavior
5 / 100
low stability is the market pricing trial risk in real time, not a random chart quirk
Source: institutional data
Institutional Activity
institutional ownership data for AVIR is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$3
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive